Plain-English translation of NCT07594769 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 study sponsored by Pfizer that tests a CGRP receptor antagonist (a type of migraine medication) in two different forms. Researchers want to understand whether a new form of the medication works the same way in your body as the currently approved form. By measuring how much medication reaches your bloodstream, they can determine if the two versions are equivalent.
Before a new formulation of a medication can be approved and used widely, it must be shown to work just as well as the existing version. This study helps ensure the new form delivers the same therapeutic benefit for people living with migraines.
You likely qualify if…
You likely don't qualify if…
You would visit the study site and take one form of the medication on an empty stomach, then return after a waiting period to take the other form. Researchers will collect blood samples at specific times to measure how much medication enters your bloodstream from each form. The entire study typically takes a few weeks, and you'll be closely monitored to ensure your safety throughout.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
Belgium